Current landscape of immunotherapy for advanced sarcoma
V Albarrán, ML Villamayor, J Pozas, J Chamorro… - Cancers, 2023 - mdpi.com
Simple Summary The systemic treatment of advanced sarcoma remains challenging.
Conventional chemotherapy and anti-angiogenic agents, even in the most responsive …
Conventional chemotherapy and anti-angiogenic agents, even in the most responsive …
Enhancing the potential of immunotherapy in paediatric sarcomas: breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors
EDG Fleuren, RL Terry, D Meyran, N Omer, JA Trapani… - Biomedicines, 2021 - mdpi.com
Despite aggressive surgery, chemotherapy, and radiotherapy, survival of children and
adolescents and young adults (AYAs) with sarcoma has not improved significantly in the …
adolescents and young adults (AYAs) with sarcoma has not improved significantly in the …
The role of immunotherapy in the management of soft tissue sarcomas: current landscape and future outlook
LB Banks, SP D'Angelo - Journal of the National Comprehensive Cancer …, 2022 - jnccn.org
Soft tissue sarcomas (STS) are a subset of sarcoma, a rare group of heterogeneous
malignancies of mesenchymal origin. Current standard of care involves surgical resection …
malignancies of mesenchymal origin. Current standard of care involves surgical resection …
Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and …
S Li, Q Sun, R Bai, Y Wang, H Wang, H Chen, Y Dong - BMC cancer, 2024 - Springer
Background The combination of immunotherapy and antiangiogenic therapy has shown
potential in the treatment of numerous malignant tumors, but limited evidence was available …
potential in the treatment of numerous malignant tumors, but limited evidence was available …
Role of Immunotherapy in Sarcomas
Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes.
Given the sheer heterogeneity of various subtypes and the rarity of the disease, the …
Given the sheer heterogeneity of various subtypes and the rarity of the disease, the …
Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy
B Wang, Y Han, J Liu, X Zhang, H Zhuo… - Frontiers in …, 2023 - frontiersin.org
Leiomyosarcoma occurring in the bone as primary tumor localization is extremely scarce
with limited cases described in the literature, accounting for less than 0.7% of all primary …
with limited cases described in the literature, accounting for less than 0.7% of all primary …